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Purpose: To report our results of nephron-sparing radiofrequency ablation (RFA) of re-
nal tumors. 
Materials and Methods: Since August 2004, 49 patients with renal tumors were treated 
with either percutaneous or laparoscopic RFA. All patients underwent preoperative 
imaging with contrast-enhanced computed tomography (CT) or magnetic resonance 
imaging (MRI) and were suspected to have renal cell carcinoma. The follow-up for each 
patient included a physical examination, chest radiography, liver function tests, and 
a contrast-enhanced CT or MRI. To confirm the pathologic criteria of complete ablation, 
30 patients underwent 6-month or 1-year follow-up biopsy. Recurrence was defined as 
growth of the tumor or any new enhancing portions at 3 months after confirmed non-
enhancement of the initial RFA lesion.
Results: Technical success was achieved in 46/49 cases (94%). The mean tumor size was 
2.4 cm and the mean follow-up period was 31.7 months (range, 6-68 months). Of 49 pa-
tients, repeated RFA was necessary in 7 patients (14%). Three patients were found to 
have recurrence at various follow-up intervals. Twenty-three patients (47%) experi-
enced complications, and all but one necessitated intervention. No distant metastasis 
was found in any cases, and all patients are alive and are being serially followed up. 
Conclusions: Percutaneous or laparoscopic RFA is considered to be a useful treatment 
for selected patients with small renal masses and for nephron-sparing. With a mean 
follow-up of 31.7 months, our intermediate data suggest excellent therapeutic outcome 
with RFA with effective local tumor control and preservation of renal function. The ulti-
mate role of this modality will continue to evolve and warrants further studies.
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INTRODUCTION
The recent advancement and widespread use of non-
invasive abdominal imaging modalities have contributed 
to increasing the detection of small renal masses (SRMs) 
[1-3]. Incidentally discovered SRMs are typically low- 
stage, slow-growing masses and are almost uniformly con-
fined to the kidney at the initial diagnosis [4]. The natural 
history of incidentally discovered SRMs remains unclear. 
However, 70% to 80% are reported to be renal cell carcino-
mas (RCCs) when excised [5-7].
　Standard treatment of localized RCC has been by either 
open or laparoscopic radical nephrectomy (RN). However, 
it has been reported that a significant number of patients 
who have only a single kidney after RN are at increased risk 
of developing chronic kidney disease (CKD) [5,8]. Lucas et 
al reported that RN carries seven times the risk of develop-
ing stage 3 CKD as in similar patients undergoing partial 
nephrectomy or radiofrequency ablation (RFA) [5]. Also, 
RN may certainly be considered over-treatment of many of 
these SRMs.
　Recent advances in surgical techniques have introduced 
the use of nephron-sparing surgery such as open and lapa-
roscopic partial nephrectomy, which have been shown to 
confer equivalent oncologic and functional outcomes to 
those of RN for patients with renal tumors smaller than 4 Korean J Urol 2011;52:531-537
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TABLE 1. Patient demographics and tumor characteristics of 49 
patients
No. of patients
Median age
Sex
　Male
　Female
Body mass index
Median follow-up months
Affected side
　Right (%)
　Left (%)
　Bilatera (%)
Tumor diameter
　Median
　≤3 cm (%)
　＞3 cm (%)
Tumor location
　Upper (%)
　Middle (%)
　Lower (%)
Tumor shape
　Exophytic (%)
　Endophytic or central (%)
Comorbid conditions
　Severe cardiovascular disease
　Severe cerebrovascular disease
　A history of other cancer
　Chronic kidney disease
　Thyroid disease
　Severe asthma
　Uncontrolled diabetes mellitus
　Jehovah’s witness
　Refusal of surgery
　Bilateral renal tumor
49
58.6 (22-76)
31
18
24 (18.45-30.98)
31.7 (6-68)
34 (69)
14 (29)
1 (2)
2.4 (1-5) cm
40 (80)
10 (20)
15 (30)
16 (32)
19 (38)
42 (84)
8 (16)
11
2
8
2
1
4
7
1
12
1
cm [9-12]. However, nephron-sparing surgery is a techni-
cally challenging procedure and is also related to increased 
perioperative complications and patient morbidity [11]. 
This is particularly true for laparoscopic partial neph-
rectomy, which requires advanced laparoscopic skills as 
well as dexterous intracorporeal suturing.
　Recently, several energy-ablative technologies have 
been actively investigated, and thermal ablative techni-
ques represent the newest frontier for active treatment of 
SRMs. The potential benefits of ablative approaches over 
extirpative techniques include reduced perioperative mor-
bidity, shorter hospital stay, faster recovery, and preserva-
tion of renal function [13]. The most attractive merit of the 
ablative technique would be to offer nephron-sparing treat-
ment to patients who are otherwise poor surgical candi-
dates. Also, thermal ablation represents a paradigm shift 
in the management strategies of malignant tumors. Here, 
malignant tissue is destroyed in situ rather than being sur-
gically removed. Surgical margin status is not considered 
as a treatment endpoint, thus further underscoring that 
principles defining successful ablation are different than 
those for surgical extirpation. 
　Radiofrequency ablation is a minimally invasive treat-
ment that was initially used for liver tumors. In 1997 Zlotta 
et al first reported RFA for renal tumors [14]. Since then, 
many reports have been published on RFA for renal tumors 
and have shown favorable outcomes in terms of local tumor 
control as well as preservation of renal function [15-18].
　We have been performing both percutaneous and laparo-
scopic RFA on select patients since August 2004 and have 
been following these patients through serial laboratory as-
sessments, imaging studies, and repeated biopsies of ab-
lated lesions. Herein, we report our experience with RFA 
of SRMs in the management of 49 patients over the past 
31.7 months. 
MATERIALS AND METHODS
Since August 2004, 49 patients with renal tumors were 
treated with either percutaneous or laparoscopic RFA. All 
patients underwent preoperative imaging with con-
trast-enhanced computed tomography (CT) or magnetic 
resonance imaging (MRI) and were diagnosed with RCC. 
Forty patients underwent percutaneous RFA and nine pa-
tients underwent laparoscopic-assisted RFA. Various rea-
sons for undergoing RFA included coexistent morbidities, 
bilateral renal tumors, high surgical or anesthetic risks, re-
ligious observances, and patient preference. Patient demo-
graphics and tumor characteristics are shown in Table 1. 
Patients were informed about other treatment options as 
well as perioperative complications and morbidities asso-
ciated with RFA. The percutaneous approach was per-
formed under both sonographic and CT guidance in 40 pa-
tients, and laparoscopic-assisted ultrasound-guided RFA 
was performed in 9. 
　Percutaneous RFA was performed in a prone or modified 
lateral position according to tumor location. The patients 
were sedated intravenously with 24 mg of midazolam hy-
drochloride (Roche, Fontenaysous-Bois, France) and 100 
to 300 mg of fentanyl citrate (Hana Pharm. Co., Hwasung, 
Korea). Local analgesia with 2% lidocaine (Huons, Hwa-
seong, Korea) was administered in combination with intra-
venous analgesia. For the laparoscopic-assisted approach, 
general anesthesia using 100 to 300 mg of propofol 
(Dongkook Pharm Co., Jincheon, Korea) was conducted in 
9 patients. A three- to four-port transperitoneal approach 
was used to perform laparoscopic-assisted RFA. The kid-
ney-surrounding tumor was exposed and the perirenal fat 
covering the tumor was removed and sent for pathology. A 
steerable laparoscopic ultrasound probe was introduced to 
visualize the tumor size and location. The electrode probe 
was placed in the deepest part of the renal tumor under re-
al-time laparoscopic ultrasound guidance. RFA was per-
formed with a 200 W generator (Radionics, Burlington, 
MA, USA) and a single (with one 2.0-3.0 cm tip) internally 
cooled electrode (Radionics, Burlington, MA, USA) with 
impedance-controlled pulsed current. The selection of the 
tip size was based on tumor size and location. Ablation time 
was a maximum of 12 min for one cycle, and the ablation Korean J Urol 2011;52:531-537
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FIG. 1. Well ablated, small intraparen-
chymal renal cell carcinoma in a 62- 
year-old male who underwent RFA. (A)
Contrast-enhanced CT scan before RF-
A demonstrates a 3.3 cm solid enhan-
cing intraparenchymal renal tumor 
located at the midpolar region of the 
right kidney. (B) Three-month follow- 
up contrast-enhanced CT scan demon-
strates no periablation enhancement 
or residual contrast enhancement wit-
hin the tumor bed, indicating technical
success.
TABLE 2. Results of RFA procedures in 49 patients
No. of patients
No. of treatments
Mean procedure time
　Laparoscopic
　Percutaneous
Incomplete ablation (%)
Complication (%)
Recurrence (%)
Technical success (%)
Overall survival rate (%)
49
70
 
124 min. (70-182)
94.8 min. (65-143)
   7 (14)
  23 (47)
  3 (6)
  46 (94)
100
RFA: radiofrequency ablation
cycle was repeated if the target temperature achieved was 
suboptimal. The guidance method used was under sonog-
raphy and CT for the percutaneous approach. On the basis 
of the size and location of the tumor, overlapping ablations 
were performed in some patients by repositioning the elec-
trode to completely ablate the entire tumor. The follow-up 
for each patient included a physical examination, chest ra-
diography, liver function tests, and a contrast-enhanced 
CT or MRI. When CT was used for guidance, a contrast- en-
hanced CT was performed to confirm complete ablation of 
the lesion and the procedure was terminated. For evalua-
tion of therapeutic efficacy, the absence of enhancement in-
side the tumor was taken to indicate technical success. If 
the tumor was enhanced, RFA was repeated. The ablation 
zone was defined by measuring the difference in the mini-
mal contrast enhancement (i.e., ＜20 Hounsfield units for 
CT) as observed on a contrast-enhanced CT after the 
ablation. Benign periablation enhancement was defined as 
a thin, concentric, and uniform rim peripheral enhance-
ment with smooth inner margins on a contrast-enhanced 
CT. On the other hand, an irregular peripheral enhance-
ment was defined as a scattered, nodular, or eccentric pe-
ripheral enhancement on a follow-up CT. A contrast-en-
hanced follow-up CT was performed to assess technical 
success and effectiveness, ablation zone, benign peria-
blation enhancement, irregular peripheral enhancement, 
and complications. A follow-up CT was conducted at inter-
vals of 1 day, 1 week, 1 month, 3 and 6 months, and then 
every 6 months thereafter. A follow-up CT at 1 day and 1 
week was conducted to assess technical success and peri-
operative complications. One-month follow-up CT was per-
formed to determine whether there was any remnant or re-
sidual enhancement of the ablated lesion. The technical 
success rate was defined as complete ablation of the tumor 
following the initial procedure or additional sessions with-
in a 1-month follow-up. Recurrence was defined as growth 
of the tumor or any new enhancing portions at 3 months 
after confirmed nonenhancement of the initial RFA lesion. 
Complications were categorized into major and minor 
complications.
RESULTS
The RFA results are summarized in Table 2. RFA was per-
formed a total of 70 times in 49 patients and technical suc-
cess was achieved in 46/49 cases (94%) (Fig. 1). The mean 
tumor size was 2.4 cm (range, 1-5.0 cm), and 42 cases (84%) 
were exophytic. The mean follow-up period was 31.7 
months (range, 6-68 months). The mean procedure time 
was 94.8 minutes (range, 65-143 minutes) for the percuta-
neous approach and 124 minutes (range, 70-182 minutes) 
for the laparoscopic-assisted approach. In a follow-up CT, 
all tumors revealed a variable degree of size reduction com-
pared to the pretreatment CT. 
　Of 49 patients, repeated RFA was necessary in 7 patients 
(14%) owing to irregular peripheral enhancement, indicat-
ing incomplete ablation on follow-up contrast-enhanced 
CT. As a result, an additional RFA procedure was man-
dated in one patient on day 1, two patients at 1 week, one 
patient at 2 weeks, one patient at 1 month, 1 patient at 2 
months, and 1 patient at 3 months on the basis of con-
trast-enhanced CT. A benign periablation enhancement 
was observed in five patients but subsequently resolved 
within 3 months of ablation. 
　A pre-RFA biopsy was taken in 13 patients who showed 
conspicuous findings of other possible renal tumors on the 
preoperative kidney CT. Five patients were diagnosed with 
RCCs, one with angiomyolipoma, and one with meta-Korean J Urol 2011;52:531-537
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FIG. 2. A recurrent cystic RCC from the
left kidney middle pole in a 63-year-old
male. (A) Thirty-month follow-up cont-
rast-enhanced CT scan shows suspici-
ous renal cyst with enhancement, left 
kidney midpole. (B) One day after 2
nd
RFA follow-up contrast-enhanced CT 
scan demonstrates no periablation en-
hancement or residual contrast enh-
ancement within the tumor bed. 
TABLE 3. Results of tumor biopsy
Pre-RFA Post-RFA
No. of patients
Renal cell carcinoma
Angiomyolipoma
Metanephric adenoma
Fibrotic tissue
Necrotic tissue
No tumor
Not performed
13
5
1
1
2
4
36
30
2
8
3
17
19
RFA: radiofrequency ablation
TABLE 4. Complications occurring during and after RFA in 49 
patients
No. of patients (%)
Major injury
　Bowel injury (%)
Minor injury
　Perirenal fluid collection(%)
　Gross hematuria(%)
　Perirenal hematoma
　Thermal injury of the psoas muscle (%)
　Thermal injury of the liver (%)
　Thermal injury of the pelvocaliceal
  system(%)
23 (47)
1 (4.3)
3 (13)
3 (13)
13 (57)
1 (4.3)
1 (4.3)
1 (4.3)
RFA: radiofrequency ablation
nephric adenoma, and six patients had fibrotic tissue or 
normal renal parenchyme. A pre-RFA biopsy was not per-
formed in the remaining 36 patients because of clear radio-
graphic findings of RCC or angiomyolipoma, the possible 
risk of bleeding, the small size of the lesion, or patient 
reluctance. To confirm the pathologic criteria of complete 
ablation, 30 patients underwent 6-month or 1-year fol-
low-up biopsy (Table 3). Follow-up biopsy was not per-
formed in the remaining 19 patients because of a previous 
renal biopsy result of benign tumors, the patients refused, 
and the possible risk of bleeding.
　Three patients were found to have recurrence at various 
follow-up intervals. Two patients were discovered to have 
recurrent tumors on follow-up biopsy. One patient had a 
viable renal tumor at the 6-month follow-up biopsy despite 
non-enhancement of the ablated lesion at the 6-month fol-
low-up CT. This patient underwent repeated RFA success-
fully and no signs of local recurrence were observed at the 
27-month follow-up. Another patient who had been treated 
with RFA for bilateral renal tumors was discovered to have 
a hyperechoic lesion of the left upper pole of the kidney at 
the 20-month follow-up ultrasound. Subsequent renal bi-
opsy confirmed a recurrent tumor and the patient under-
went RN. Another patient who had undergone successful 
RFA for a left low renal tumor developed a new cystic renal 
tumor with enhancement on the midpole of the left kidney 
at the 30-month follow-up CT. Repeated RFA was per-
formed successfully and no recurrence has been observed 
for 11 months since the last RFA (Fig. 2). No distant meta-
stasis developed during the mean follow-up of 31.7 months. 
　Concerning the effect of RFA on preserving renal function, 
serum creatinine levels did not change compared with 
those before RFA. Four patients showed a slight increase 
in creatinine levels (from 1.2 to 1.5 mg/dl, from 1.3 to 1.7 
mg/dl, from 1.1 to 1.5 mg/dl, and from 1.3 to 1.6 mg/dl); how-
ever, levels returned to baseline levels after 7 to 10 days. 
　Twenty-three patients (47%) experienced complications 
(Table 4). The most common complication was perinephric 
hematomas, which occurred in 13 patients and were man-
aged conservatively. Gross hematuria was seen in 3 pa-
tients but all resolved within a few days. Perinephric fluid 
collection was seen in 3. One patient had a mild thermal 
injury of the psoas muscle. Another patient suffered from 
bowel injury with mild hydronephrosis during laparo-
scopic-assisted RFA. This patient underwent ileostomy di-
version and, later, the ileostomy was reverted after 4 
months and mild hydronephrosis was resolved within 1 
month. Another patient had thermal injury to the liver that 
was managed with conservative treatment. In addition, 
another patient had a small amount of contrast leakage in-
to the perirenal space suggesting thermal injury of the pel-
vocaliceal system at the 1-year follow-up CT. This patient 
was managed conservatively without any adverse effects. 
Serum creatinine levels were below the normal range in 
this patient and no symptoms were observed in the sub-
sequent follow-up. Korean J Urol 2011;52:531-537
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DISCUSSION
Recent advancements in radiologic imaging have led to the 
increased incidence of small and localized renal tumors. 
Refinements in surgical techniques with better imaging 
modalities have resulted in an evolution of nephron-spar-
ing surgeries such as open and laparoscopic partial neph-
rectomy [9-12].
　RFA was initially introduced to treat selected patients 
who had high surgical or anesthetic risk, a solitary tumor, 
or multifocal renal tumors. Various reports on local tumor 
control have so far been promising [15-18]. In the present 
series, we achieved complete control of renal tumors in 94% 
of cases with a mean follow-up of 31.7 months, which is 
quite comparable other series. 
　The outcomes of RFA are affected by the following fac-
tors: tumor size and location, tissue impedance, ablation 
time, amount of energy delivered, and surface area of the 
electrodes. Gervais et al reported in a multivariate analysis 
of 85 patients who underwent percutaneous RFA that 
small tumor size and a noncentral location of the tumor 
were independent significant predictors of complete ne-
crosis after a single RFA session [15]. Furthermore, 
Mylona et al reported a complete response of 85.7% for tu-
mors less than 3 cm after first RFA but reported a notice-
ably smaller response rate with tumors greater than 5 cm 
in size [19]. In our experience, tumors greater than 3 cm 
were technically challenging to completely ablate with only 
one ablation and required multiple overlapping ablations. 
Therefore, smaller renal tumors are ideal candidates for 
obtaining a complete response at first RFA. 
　Tumor location may also influence ablative outcome. It 
is reported that the ablative effect on a centrally located tu-
mor is lower because of the heat sink effect of central blood 
vessels near the renal hilum, in which a regional vascular 
flow reduces the extent of the thermally induced coagu-
lation [15,20]. By contrast, the ablative effect on exophytic 
tumors is higher because they are easy to target with the 
RFA probe and because of the insulating effect of the sur-
rounding perirenal fat, which allows the achievement of 
higher temperatures during RFA [15,20]. 
　In our study, local tumor control was similarly worse for 
tumors adjacent to the renal hilum. Also, local tumor con-
trol for tumors located in the upper pole of the kidney tend-
ed to be less favorable than that for tumors located in the 
middle or lower pole. This outcome may be due to the diffi-
culty of needle insertion at the upper pole of the kidney, 
which is always covered by the ribs, spleen, lung, and liver. 
However, whether the tumor was exophytic or endophytic, 
this was not related to the outcome except when the tumor 
was endophytic in a medial central location. 
　We performed RFA using percutaneous CT guidance. 
Percutaneous CT guidance allows more reliable electrode 
placement, and the gas production at the ablation site does 
not obscure target lesion for additional overlapping 
ablation. 
　For patients with difficult access, such as patients with 
multiple lesions in a solitary kidney, an intervening lung 
parenchyma or bowel, or thin patients with an anterior le-
sion, laparoscopy-assisted ultrasound guidance or open in-
traoperative RFA should be considered as a treatment 
option. In our study, nine patients were treated with a lapa-
roscopy-assisted ultrasound-guided RFA to isolate the tar-
geted tumors away from adjacent normal structures, such 
as liver, colon, spleen, or psoas muscle. 
　The criteria of therapeutic response were based on the 
report by Goldberg et al [21]. Complete response was de-
fined as the absence of any enhancement within the tumor 
as observed in the contrast-enhanced CT or MRI. A benign 
periablation enhancement, which can measure up to 12 
mm, typically suggests a transient benign physiologic re-
sponse to a thermal injury and may persist up to 3 months 
after the ablation. An irregular peripheral enhancement 
represents a residual tumor that may occur at the ablative 
margin. This lesion grows in a scattered, nodular, or eccen-
tric pattern, which indicates incomplete local control. In 
our study, irregular peripheral enhancement was noted in 
12 tumors at 1 day and 1 week. Five patients were found 
to have benign artifact on follow-up. The other seven pa-
tients underwent additional RFA sessions over period of 1 
to 3 months.  
　Recently, the importance of post-RFA biopsy was demon-
strated by Weight et al [22]. In 6 of 24 patients who under-
went post-RFA biopsy, viable tumor cells were revealed in 
patients who otherwise had no evidence of enhancement 
on follow-up CT or MRI. The same authors saw no viable 
tumors at their 6-month follow-up biopsy after cryoa-
blation and no contrast enhancement on follow-up CT. 
Thus, the authors concluded that postcryoablation con-
trast enhancement was a reliable tool and that follow-up 
biopsies were of low value, whereas after RFA, radiologic 
findings were not reliable and follow-up biopsies had an im-
pact on further decision making. The authors proposed bi-
opsy of ablated sites in RFA follow-up protocols. Also, 
Arima et al examined ablated tumor specimens removed 
6 weeks after RFA and discovered that the tumor speci-
mens showed well-preserved cancer cells under hematox-
ylin and eosin staining. However, almost all the cells were 
stained with terminal dUTP nick end labeling (TUNEL) 
staining, which is used to detect apoptosis [23]. We have 
been performing follow-up biopsy after initial RFA. Thirty 
patients underwent 6-month or 1-year follow-up biopsy. 
Two patients were discovered to have recurrent tumors on 
follow-up biopsy. The first patient who showed viable tu-
mor cells in the biopsy otherwise demonstrated no evidence 
of enhancement at the 6-month follow-up CT. This patient 
underwent repeated RFA and had no signs of recurrence 
at the 27-month follow-up CT after second the RFA. The 
second patient had a bilateral renal tumor that was treated 
with simultaneous bilateral RFA. At the 2-year follow-up 
CT, the patient showed enhancement of the previously ab-
lated left kidney lesion and underwent laparoscopic RN be-
cause the lesion location was very difficult to target. The 
patient is free of recurrence as demonstrated at the Korean J Urol 2011;52:531-537
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46-month follow-up CT after RN.
　Complications of RFA can be divided into major (requi-
ring intervention) and minor complications (conservative 
observation). The reported complications include peri-
nephric hematoma, gross hematuria, pyonephrosis, ure-
teral stricture, damage to adjacent organs, pain, and par-
esthesias [24,25]. In the present study, 23 (47%) complica-
tions occurred, which included perinephric hematoma in 
13, gross hematuria in 3, perinephric fluid collection in 3, 
a mild thermal injury of the psoas muscle, a bowel injury 
with mild hydronephrosis, a liver injury, and thermal in-
jury of the pelvocaliceal system. Most of the complications 
were managed conservatively except one. Inadvertent 
bowel injury with mild hydronephrosis occurred during 
laparoscopic-assisted RFA and the patient underwent 
emergent ileostomy after completion of RFA. Serum crea-
tinine levels were measured in all of our patients, but we 
observed no deterioration of renal function 3 months after 
RFA compared with preoperative creatinine levels. How-
ever, four patients had transient elevation of serum crea-
tinine levels after RFA; these patients had mildly elevated 
serum creatinine levels preoperatively, and 1 week later, 
they returned to preoperative levels. The results were sim-
ilar when the analysis was limited to those patients with 
preoperative renal impairment.
　The local recurrence rate varies from 0% to 11.1% in cases 
in which technical success is achieved during the initial 
RFA [15,18,26]. In our patients, there were 3 patients with 
local recurrence among 49 patients (6%). With a mean fol-
low-up of 31.7 months, no distant metastasis has been 
observed. In this study, the overall survival rate was 100%. 
Despite our favorable intermediate follow-up data, a lon-
ger follow-up period may be needed to detect recurrence ra-
diologically after RFA. Also, T1a renal masses are gen-
erally known to have low malignant potential, and there-
fore it may take quite a while to have metastatic extension 
from a local recurrence after RFA.
CONCLUSIONS
Our intermediate data suggest excellent therapeutic out-
comes with RFA with achievement of effective local tumor 
control and preservation of renal function. Although the 
mean follow-up period in this study was relatively short, 
our experience with RFA demonstrates that it is a safe and 
effective treatment for small, localized renal tumors in a 
selected group of patients.
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